LAPTM4B and breast carcinoma: Odds ratio analysis showed that LAPTM4B*1/2, *2/2 and LAPTM4B (*1/2+*2/2) were associated with a significant increased risk of breast cancer compared with LAPTM4B*1/1 (OR = 1.328, 95% CI = 1.106–1.595; OR = 1.147, 95% CI = 1.046–1.257; and OR = 1.413, 95% CI = 1.169–1.707, respectively).